Editorial

Quinine – a time for re-evaluation?

G A Richards

Abstract


Quinine was the drug of choice for severe malaria until 2005 and was used extensively in South Africa for this purpose. As discussed in this issue of the SAJCC by Mathiba et al. from Chris Hani Baragwanath Hospital (CHBH), two large randomised controlled trials (SEAQUAMAT (South East Asian Quinine Artesunate Malaria Trial) and AQUAMAT (African Quinine v. Artesunate Malaria Trial)) conducted in adults and children, respectively found that mortality was significantly lower with intravenous artesunate and as such it became the recommended agent for severe malaria.


Author's affiliations

G A Richards, Department of Critical Care, University of the Witwatersrand, Johannesburg, South Africa; and Department of Critical Care, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa

Full Text

PDF (96KB) HTML

Cite this article

Southern African Journal of Critical Care 2019;35(1):4-5. DOI:10.7196/SAJCC.2019.v35i1.367

Article History

Date submitted: 2019-08-15
Date published: 2019-08-15

Article Views

Abstract views: 43
Full text views: 49

Comments on this article

*Read our policy for posting comments here